Shared genetics underlying epidemiological association between endometriosis and ovarian cancer


1Statistical Genetics, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia
2Molecular Cancer Epidemiology, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia
3Institute of Health and Biomedical Innovation, Queensland University of Technology, Queensland, Australia
4Population Health Department, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia
5Research Division, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Australia

© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com
6Genetic and Genomic Epidemiology Unit, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
7University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology
8University Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Universitaetsstrasse 21-23, 91054 Erlangen, Germany
9Laboratory for Translational Genetics, Department of Oncology, University of Leuven, Belgium
10Vesalius Research Center, VIB, Leuven, Belgium
11Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
12Department of Community and Family Medicine, Section of Biostatistics & Epidemiology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA
13Department of Epidemiology, University of Washington, Seattle, WA, USA
14Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
15German Cancer Research Center, Division of Cancer Epidemiology, Heidelberg, Germany
16Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany
17Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
18Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA
19Radiation Oncology Research Unit, Hannover Medical School, Hannover, Germany
20Gynaecology Research Unit, Hannover Medical School, Hannover, Germany
21Department of Gynecology, Jena-University Hospital-Friedrich Schiller University, Jena, Germany
22Clinics of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany
23N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus
24Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
25Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
26Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
27Womens Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
28Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
29Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA
30The University of Texas School of Public Health, Houston, TX, USA
31Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
32Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
33Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
34Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia
35 Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia
36 Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
37 Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
38 College of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas, USA
39 Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
40 Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
41 Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital, Boston, Massachusetts, USA
42 Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
43 Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
44 Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
45 Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway
46 Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway
47 Radboud University Medical Centre, Radboud Institute for Health Sciences, Nijmegen, Netherlands
48 Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
49 Radboud university medical center, Radboud Institute for Molecular Life Sciences, Department of Obstetrics and Gynaecology, Nijmegen, The Netherlands
50 Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada
51 Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC Canada
52 Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York, NY, USA
53 Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford CA, USA
54 Division of Epidemiology and Biostatistics, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA
55 Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada
56 Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada
57 International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
58 Institute of Nursing and Health Sciences, Medical Faculty, University of Rzeszów, Poland
59 The Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
60 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda MD, USA
61 M. Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland
62 Public Health Ontario, Toronto, ON, Canada
63 Women’s College Research Institute, University of Toronto, Toronto, Ontario, Canada
Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA
Department of Epidemiology, University of California Irvine, Irvine, California, USA
Center for Cancer Genetics Research & Prevention, School of Medicine, University of California Irvine, Irvine, California, USA
Faculty of Medicine, University of Southampton, Southampton, UK
Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA
Women's Cancer, Institute for Women's Health, University College London, London, United Kingdom
Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA
Department of Pathology and Laboratory Diagnostics, the Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
Department of Obstetrics, Gynecology and Oncology, IInd Faculty of Medicine, Warsaw Medical University and Brodnowski Hospital, Warsaw, Poland
Department of Laboratory Medicine and Pathology, Division of Experimental Pathology, Mayo Clinic, Rochester, MN, USA
Department of Biostatistics, University of Kansas, Kansas City, Kansas, USA
Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
Departments of Pathology and Obstetrics & Gynecology, OHSU, Portland, OR, USA
Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA
Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota, USA
Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina, USA
Cancer Control and Population Sciences, Duke Cancer Institute, Durham, North Carolina, USA
Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA
Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA
The Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
Molecular Epidemiology, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia
Endometriosis CaRe Centre, Nuffield Dept of Obstetrics & Gynaecology, University of Oxford, UK
Genetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia

*To whom correspondence should be addressed at: Associate Professor Stuart Macgregor, QIMR Berghofer Medical Research Institute, Locked Bag 2000, Herston, QLD 4029, Australia. Tel: +61 738453563; Fax: +61 733620101; Email: stuart.macgregor@qimrberghofer.edu.au
Abstract

Epidemiological studies have demonstrated associations between endometriosis and certain histotypes of ovarian cancer, including clear cell, low-grade serous and endometrioid carcinomas. We aimed to determine whether the observed associations might be due to shared genetic aetiology. To address this, we used two endometriosis datasets genotyped on common arrays with full-genome coverage (3,194 cases and 7,060 controls) and a large ovarian cancer dataset genotyped on the customised iCOGS arrays (10,065 cases and 21,663 controls). Previous work has suggested that a large number of genetic variants contribute to endometriosis and ovarian cancer (all histotypes combined) susceptibility. Here using the iCOGS data, we confirmed polygenic architecture for most histotypes of ovarian cancer. This led us to evaluate if the polygenic effects are shared across diseases. We found evidence for shared genetic risks between endometriosis and all histotypes of ovarian cancer, except for the intestinal mucinous type. Clear cell carcinoma showed the strongest genetic correlation with endometriosis (0.51, 95% CI=0.18-0.84). Endometrioid and low-grade serous carcinomas had similar correlation coefficients (0.48, 95% CI=0.07-0.89 and 0.40, 95% CI=0.05-0.75, respectively). High-grade serous carcinoma, which often arises from the fallopian tubes, showed a weaker genetic correlation with endometriosis (0.25, 95% CI=0.11-0.39), despite the absence of a known epidemiological association. These results suggest that the epidemiological association between endometriosis and ovarian adenocarcinoma may be attributable to shared genetic susceptibility loci.
Introduction

Ovarian cancer is the most fatal gynaecological cancer. It is not a single disease but comprises a number of histotypes (1). The most common subtype is serous carcinoma, accounting for over 50% of all invasive epithelial ovarian cancers (EOC). Recent morphological and molecular genetic studies have confirmed that invasive serous EOC should be further sub-categorized into high-grade and low-grade types (2, 3). The clear cell, endometrioid and mucinous EOCs are three most common non-serous tumours. The heterogeneity among EOC subtypes is manifested in differences in risk factors, germline and somatic mutations, gene expression and chemotherapy responsiveness (4).

Endometriosis is a common gynaecological disorder associated with pelvic pain and sub-fertility, affecting 10-15% of women of reproductive age (5). The disease is defined as the presence of endometrial-like tissue outside the uterine cavity, primarily on pelvic organs. The disease is typically staged using the revised American Fertility Society (rAFS) classification (6) based on the differential location of the lesions (ovarian, peritoneal, recto-vaginal), extent of disease, and adhesion formation.

The epidemiological link between endometriosis and ovarian cancer was first identified in 1925 (7), and has been largely replicated since (8). Some studies have suggested that the link might differ between ovarian cancer histotypes (9-11). Recently, a large collaborative effort by the Ovarian Cancer Association Consortium (OCAC) reported that endometriosis increases the risk of clear cell ovarian cancer by 3-fold, and the risk of low-grade serous and endometrioid subtypes by ~2-fold, but that endometriosis was not associated with other
histotypes (12).

Despite the convincing epidemiological link, the mechanisms underlying the co-occurrence of endometriosis and ovarian cancer are unknown. Several studies have attempted to demonstrate a causal relationship between the two conditions via the identification of somatic mutations that may represent early events in the transformation of benign endometriotic lesions in the ovary (endometrioma) to malignancy. For example, one study identified truncating mutations in *ARID1A* that cause loss of expression of BAF250 protein in both clear cell and endometrioid tumours, and in two cases the same mutations were found in endometriotic lesions adjacent to the tumours (13).

An alternative explanation is that the observed associations may arise from shared germline genetic risk factors, but this has not been well explored (5, 14). Traditionally, studying genetic correlation requires large family or twin studies with phenotypic data for both diseases. However, because of the rare co-occurrence of EOC (particularly of the rare histotypes) and endometriosis in families, ascertaining sufficient cases for family studies is difficult. Recently, germline genetic variants predisposing women to the two diseases have been identified from genome-wide association studies (GWAS) (15-21). With the exception of the locus at 1p36 (nearest gene: *WNT4*) (20, 22), there is limited overlap in the susceptibility loci for the two diseases, which seems to lend little support to the hypothesis of shared genetic factors underlying the two diseases. However, we and others have previously shown that germline genetic contributions to ovarian cancer and to endometriosis are not simply limited to the genome-wide significant variants from GWAS; instead many more genetic variants that do not pass the genome-wide significant threshold contribute to the disease heritability (23, 24). Therefore, to study shared genetic risks between the two
diseases, we need to extend beyond genome-wide significant variants.

In the current study, we applied two complementary statistical genetic methods, genomic-relatedness-matrix restricted maximum likelihood (GREML) (25, 26) and genetic risk prediction (GRP) (27), both of which evaluate the joint contribution of all germline genetic variants captured on the genotyping arrays. The first method predicts the phenotypic similarities from the genomic relatedness between individuals with distant relationships, thus estimates array heritability (that is, the heritability attributable to the variants on the genotyping array) in the univariate case or genetic correlation/co-heritability in the bivariate case. The second method selects genetic variants from a discovery set according to their associations with the trait assessed, and constructs polygenic risk scores in an independent replication set using the selected variants and weights from the discovery. An association of risk scores with the trait in the replication set indicates genetic risks overlap between the two traits assessed. Both methods allow the use of independent datasets for each phenotype of interest, thus circumventing the ascertainment issue in traditional quantitative genetic designs. In addition to investigating the shared genetic risks between endometriosis and ovarian cancer, we also estimated the array heritability specific for EOC histotypes.

Results

Array heritabilities of EOC histotypes

In previous work, we applied the GREML method implemented in the software Genome-wide Complex Trait Analysis (GCTA) to ovarian cancer (all histotypes combined), and estimated that the array heritability was 30%. That is, 30% of variance in risk of ovarian cancer was attributable to the common variants on commercial genotyping arrays (24).

However, the sample size in the previous study was insufficient for the estimation of array
heritability for the various histotypes. Here we used a larger collection of ovarian cancer case-control data from the OCAC genotyped using the customised Illumina Infinium iSelect arrays (iCOGS; sample sizes by histotypes and study sites in Supplementary Table 1). We found significant, albeit small, array heritabilities for all major invasive EOC histotypes except for mucinous and low-grade serous diseases (Table 1). The most common EOC subtype, high-grade serous, had the highest array heritability, 8.8% (95% CI=6.8-10.8%), followed by clear cell, 6.7% (95% CI=0.3-13.1%), and endometrioid, 3.2% (95% CI=0.06-6.3%). The mucinous and low-grade serous EOC were estimated to have null array heritability. Overall, 5.6% (95% CI=4.4-6.7%) of variance on the liability scale can be explained by the SNPs on the iCOGS array for all invasive EOC, regardless of histotypes.

We also carried out a control-control contrast study, dividing 21,663 controls into four pseudo case-control sets (Methods). We estimated the array heritability in each pseudo case-control set, none of which were significantly different from zero (maximum \( h^2_g \) =2.8%, P=0.37; Supplementary Table 2).

**Shared genetics between EOC subtypes and endometriosis**

When assessing shared genetics between ovarian cancer subtypes and endometriosis, the number of SNPs common to the arrays used in these two datasets was reduced to ~84K. Nonetheless, we found strong genetic correlations between endometriosis and clear cell EOC \( (r_g =0.51, 95\% \ CI=0.18-0.84) \) and endometriosis and endometrioid EOC \( (r_g =0.48, 95\% \ CI=0.07-0.89) \), and a moderate genetic correlation between endometriosis and serous EOC \( (r_g =0.29, 95\% \ CI=0.16-0.42) \). Interestingly, despite a null array heritability for low-grade serous EOC, its genetic correlation with endometriosis was significant \( (r_g =0.40, 95\% \ CI=0.05-0.75) \). The correlation coefficient was lower for high-grade serous EOC \( (r_g =0.25, 95\% \ CI=0.11-0.39) \) compared to low-grade serous disease. In contrast, no evidence was
apparent for genetic correlation between endometriosis and the mucinous histotype ($r_g = -0.01$, 95% CI= -0.44-0.42). Overall, the genetic correlation between all invasive EOC and endometriosis was estimated to be 0.40 (95% CI=0.26-0.54).

We then performed the GRP analyses in two ways, firstly assessing whether the risk scores calculated from summary results of EOC subtypes were associated with endometriosis, and secondly, whether the risk scores calculated from endometriosis were associated with EOC histotypes. The results from the risk score analyses were highly consistent with the estimated genetic correlations (Figure 1a-b). The risk scores from low-grade serous, endometrioid and clear cell EOC histotypes predicted endometriosis risks, and the risk scores of endometriosis predicted all EOC subtypes but mucinous. Also, the risk scores of endometriosis were more strongly associated with low-grade serous EOC than with high-grade serous disease. The results remained almost unchanged in sensitivity analyses where we restricted the GRP analysis to the less-related samples from endometriosis and OCAC datasets (genetic relatedness < 0.1, Supplementary Figure 1) or to the set of SNPs clumped to reduce LD (~44K SNPs with $r^2<0.2$, Supplementary Figure 2), except that the association between endometriosis and endometrioid EOC was weaker in the latter case.

The epidemiological association between EOC and endometriosis means that women with ovarian cancer are more likely to have a history of endometriosis compared to the general female population. Hence we investigated whether the observed genetic overlaps between EOC and endometriosis arose from women with both diseases. We used self-reported data on endometriosis from the OCAC (12) to exclude women with histories of endometriosis or with missing data. A limitation here was that a few OCAC studies did not ascertain endometriosis status, thus the sample size for this sub-analysis was substantially reduced (nearly 45%
reduction). Nonetheless, we found the risk scores calculated from the discovery set of endometriosis were still significantly associated with high-grade serous, low-grade serous and endometrioid EOC (Figure 1c). The significance of the genetic overlap between endometriosis and clear cell EOC was, however, considerably attenuated.

**Psychiatric Genomics Consortium (PGC) data as negative controls**

We used the PGC data for negative control experiments because psychiatric disorders are not likely to share genetic risk factors with the two gynaecological diseases studied here. We examined the genetic overlaps of endometriosis and ovarian cancer with schizophrenia and bipolar disorder in the GRP analyses (28, 29). Based on ~130-170K overlapping SNPs, we found no associations of risk scores from schizophrenia or bipolar disorder with all invasive EOC (P>0.1 for all P-values; Supplementary Figure 3). Since the control subjects from the Wellcome Trust Case Control Consortium (WTCCC) study were included in the PGC data, and also used as the controls for the UK endometriosis study, we only assessed the polygenic risk scores from the two psychiatric disorders in the Australian endometriosis data. Based on analysis of 440-470K overlapping SNPs, we found no evidence for genetic overlap between endometriosis and schizophrenia or bipolar disorder (P>0.1 for all P-values; Supplementary Figure 3).

**Discussion**

Whilst various studies have demonstrated a consistent epidemiological association between endometriosis and risk of ovarian cancer, the underlying mechanism is not clear. Here we examined whether shared genetic risk factors, beyond the limited number of genome-wide significant variants, might underlie the observed association.
On the premise of polygenic architecture of both diseases (23, 24), we derived the shared genetics from the aggregate effect of germline genetic variants captured on genotyping arrays, using two complementary statistical genetic methods, GREML and GRP. Both methods have been widely applied to investigate shared genetics between traits and diseases (25, 27, 30-32). The bivariate GREML method provides unbiased estimates of genetic correlation. However, it requires genotype data that may not be readily available in many cases, whereas the GRP method only requires summary results from the discovery set (although care needs to be taken to ensure no subject overlaps between the discovery and target sets). The results from our control-control contrast and negative control experiments showed that the two methods are reliable and that the results we presented here are unlikely to be artefacts.

Further to our previous work which estimated array heritability for ovarian cancer (all histotypes combined), we reported the array heritabilities from the customised iCOGS genotyping array, for individual histotypes of ovarian cancer. Among five major EOC histotypes, we found significant array heritability for high-grade serous (8.8%, 95% CI=6.8-10.8%), clear cell (6.7%, 0.3-13.1%) and endometrioid EOC (3.2%, 0.06-6.3%), but not in mucinous or low-grade serous disease. To our knowledge, because of the low disease prevalence, no family or twin studies have examined EOC histotypes. Through the large OCAC dataset, we were able to estimate, for the first time, the array heritabilities specific for the histotypes. However, compared to our previous estimate of 30% heritability for all invasive EOC using Illumina Human610-Quad and Human1M-Duo arrays (24), the estimates presented here are small due to the limited genome coverage on the iCOGS array. The iCOGs array includes 211K SNPs (195K post QC in our analyses) although many of these are concentrated on particular regions of the genome, with little or no coverage of some genomic
regions. In contrast, the 471K SNPs common to Illumina Human610-Quad and Human1M-Duo arrays provide an even coverage of most of the genome. For the histotypes that did not show significant array heritabilities (mucinous and low-grade serous EOC), the true heritabilities may be too low to be detected with the current case numbers, or the underlying SNPs may not be well represented on the iCOGS array. We acknowledge that the estimates would be more informative if such large dataset were genotyped on the arrays with full-genome coverage.

We found widespread shared genetics between endometriosis and most EOC histotypes. The strong genetic correlations of endometriosis with clear cell EOC ($r_g = 0.51$, 95% CI=0.18-0.84), with endometrioid EOC ($r_g = 0.48$, 95% CI=0.07-0.89) and with low-grade serous EOC ($r_g = 0.40$, 95% CI=0.05-0.75), were consistent with epidemiological links between endometriosis and these EOC histotypes (12). Our results therefore suggest that shared genetics partly explains the observed link between endometriosis and EOC for these histotypes. Interestingly, we observed a weaker but significant genetic correlation between endometriosis and high-grade serous EOC ($r_g = 0.25$, 95% CI=0.11-0.39), despite the absence of a known epidemiological association (12). The weaker correlation may reflect that high-grade serous carcinoma often arises from fallopian tubes (33). The specific lack of association with mucinous EOC dovetails with the lack of epidemiological risk factors for that tumour type (11). Overall, the genetic correlation between all invasive EOC and endometriosis was 0.40 (95% CI=0.26-0.54). In addition, the shared genetics between endometriosis and EOC histotypes, except for clear cell, remained after the exclusion of women with histories of endometriosis, suggesting that our results were unlikely to be solely attributable to women with both diseases. Compared to the other EOC histotypes, the attenuated results in clear cell EOC was likely due to the largest reduction in the case
numbers, which was expected given that the epidemiological association is the most pronounced between endometriosis and this histotype. The genetic overlap between endometriosis and most EOC histotypes suggest that women with endometriosis may be at elevated risk of later EOC. Bearing in mind that the germline genetic contribution to absolute risk is relatively small, it will be of interest in future studies to quantify better how genetic predisposition to endometriosis confers risk of EOC.

In light of substantial heterogeneity among ovarian cancer histotypes (4), here we investigated the shared genetics between endometriosis and ovarian cancer, stratified by ovarian cancer histotypes. Further investigation of the links stratified by different stages of endometriosis may be worthwhile, especially in the localised form of ovarian endometriosis (also known as endometriomas). By rAFS classification, endometriomas falls in stage III/IV (moderate to severe endometriosis) (6). Interestingly, a previous study showed increased genetic loading in women with moderate to severe endometriosis compared to those with minimal disease (19).

It is worth noting that our results were derived either from SNPs on the iCOGS array or from the overlap of SNPs on the iCOGS and commercial GWAS arrays. Hence, the numbers of SNPs included in the analyses were appreciably smaller than the numbers in a typical GWAS. Analyses can be performed on imputed data; however, since the SNPs on the iCOGS array were not designed to tag the whole genome, imputation would still be limited to certain genomic regions that are represented on the array. Further analyses will be warranted when the more comprehensive genotyping array, Infinium OncoArray-500K BeadChip, which integrates a genome-wide backbone of 250,000 tag SNPs, becomes available.
In summary, using the large OCAC dataset genotyped on the iCOGS array, we established that the majority of ovarian cancer histotypes have a polygenic architecture. More importantly, we found that genetic risks overlap between endometriosis and all histotypes of ovarian cancer except for mucinous. These results suggest that the epidemiological association between endometriosis and ovarian cancer is, at least partly, attributable to shared genetics. Therefore, future studies should focus on identifying common molecular pathways underlying both diseases.

**Materials and Methods**

**Data**

We used two GWAS datasets of surgically confirmed endometriosis cases from International Endogene Consortium (IEC) in this study, one from Australia and the other from the UK (19, 23). In the Australian study, 2,270 women with endometriosis were recruited from QIMR Berghofer Medical Research Institute and genotyped using Illumina Human670Quad BeadArrays. The controls were 1,870 unrelated Australians from an adolescent twin study recruited in the same institute, genotyped using Illumina Human610Quad arrays. The UK cases (n=924) were recruited through the University of Oxford and also genotyped on Illumina Human670Quad BeadArray. We used 5,190 individuals from the WTCCC who were genotyped on the Illumina Human1M-Duo array as the UK controls. We applied standard quality control (QC) to the Australian set, that is, subjects with >5% missing genotypes were excluded, as were SNPs with minor allele frequencies <0.01, call rates <0.99 or p-values from testing Hardy-Weinberg equilibrium <0.0001 (24). As noted before (23, 24), the UK dataset using WTCCC controls required more stringent QC, so additional QC criteria including differential missingness between cases and controls (P<0.001) and two-locus QC
(34) (P<0.02) were applied. We merged the two datasets for analyses (SNPs with strand-ambiguous alleles were excluded), yielding genotype data on a common set of 483,940 SNPs for 3,194 cases and 7,060 controls, all of European ancestry (19).

For ovarian cancer, we used data from OCAC study which comprises 47,630 cases and controls from 43 studies genotyped using the iCOGS arrays. This array was designed to accommodate 211,155 SNPs that were selected as either GWAS replication, fine-mapping or candidate SNPs from breast, prostate and ovarian cancer consortia. The details of array design and QC have been described elsewhere (15). We applied similar QC, except that we selected only subjects of European ancestry and with invasive EOC tumours of clearly identified histotypes. In total, data from 10,065 women with invasive EOC (4121, 1350, 662, 621, and 363 for the high-grade serous, endometrioid, mucinous, clear cell, and low-grade serous histotypes, respectively) and 21,663 controls, typed for 195,183 SNPs, were available for analyses (see Supplementary Table 1 for details of individual OCAC studies).

Analysis

We applied two statistical genetic approaches in this study. The first approach was GREML, which involved the estimation of genetic relatedness between subjects using genotyping array data and links the resultant relationship matrix to univariate or bivariate phenotype(s). We used GCTA (35) to construct the relationship matrix using all available SNPs post QC. In the univariate analysis of EOC histotypes, the genetic relatedness of subjects with the corresponding EOC histotype was estimated using variants on the iCOGS arrays and compared to the relatedness among OCAC controls in order to estimate array heritabilities ($h^2_g$). Intuitively, the array heritability is high when case-case and control-control pairs are more genetically similar than case-control pairs (that is, individuals with higher genetic relatedness share more similar phenotype). In the bivariate analyses of endometriosis and
EOC histotypes, the genetic relatedness of subjects in one case-control set was compared with relatedness in the other set, thus to estimate genetic correlation \( r_g \) between the two diseases. The genetic correlation is zero when genetic relatedness among cross-trait case-case pairs are the same as cross-trait case-control pairs; it is positive when relatedness among cross-trait case-case pairs are higher than among cross-trait case-control pairs, and negative when relatedness among cross-trait case-case pairs are lower than cross-trait case-control pairs (32).

In the GREML analyses, we excluded closely related individuals to avoid confounding from shared environmental factors. For endometriosis datasets, a very stringent relatedness threshold was applied (genetic relatedness between samples < 0.025, approximately equivalent to the relatedness between 3rd-4th cousins); while for EOC data on iCOGS arrays, we applied a less stringent threshold in order to retain sufficient sample size for rare EOC histotypes (relatedness < 0.1, less than 1st cousin; we also applied a threshold of 0.05 as a sensitivity check, see Supplementary Table 3). All analyses were adjusted for ten principal components (PCs) and for study site. We also transformed the array heritability on the observed binary scale to an underlying quantitative liability scale taking into account the disease prevalence. According to the Surveillance, Epidemiology, and End Results Program DevCan database (SEER 18 Incidence and Mortality, 2014 submission; http://surveillance.cancer.gov/devcan/canques.html), the lifetime risk of ovarian cancer by the age of 80 is 1.07% (1.37% by age 95+) in 2010-2012 for non-Hispanic whites (the race of subjects in the present study; 1.00% for all races). Since 80-90% of all ovarian malignancies are invasive disease (36), we used 0.9% as the prevalence of invasive EOC in this study (also used 1% as a sensitivity check, Supplementary Table 3). The prevalence of individual EOC histotype was then calculated as the prevalence of all invasive EOC times the fraction of the...
corresponding histotype (37) (values of prevalence are listed in Table 1). \( r_g \) estimates are approximately the same on the observed and the liability scales, thus not dependent on disease prevalence (25).

Our second approach was GRP based on the aggregate effects of many genetic variants; one data set serves as the discovery set, with associations examined in a second replication set (27). The genetic risk scores of individuals in the replication set were calculated as the sum of their risk alleles weighted by the allelic effects that were estimated from the discovery set. These risk scores were then examined for associations with disease status in the replication set, while adjusting for PCs and study site. This method requires duplicate samples in the discovery and replication sets to be removed (e.g., the same individual present in the endometriosis data and OCAC studies). We used genetic relationship calculated from GCTA to identify duplicate samples (with relatedness > 0.85), and excluded one in each pair from the analyses. To assess the impact of relatedness, we also applied the relatedness threshold of 0.1 as a sensitivity check (Supplementary Figure 1). When calculating risk scores, we used SNPs without clumping for high linkage disequilibrium (LD; we also applied LD clumping, i.e., dropping the SNPs in high LD with index SNPs, as a sensitivity check, Supplementary Figure 2). The risk scores were calculated in PLINK (38), and logistic regression was performed in R.

**Control-control contrast studies and negative control experiments**

To evaluate the reliability of the two approaches, we conducted control-control contrast studies using OCAC controls and negative control experiments using data from the PGC. For control-control contrast studies, we split 21,663 OCAC controls into eight sets (seven sets had 2,694 subjects and one set had 2,805 subjects), which were then randomly assigned as four pseudo case-control sets. We performed the univariate GREML analyses on these sets.
Since we did not have access to the full genotype data from the PGC, we only performed the GRP analyses in the negative control experiments. The publically available GWAS summary results for the two major psychiatric conditions, schizophrenia and bipolar disorder (both from studies with approximately 20,000 case and control subjects (28, 29)) were used to calculate the genetic risk scores in our endometriosis and OCAC datasets.

**Funding**

This study was supported by the QIMR Berghofer-Weekend to End Women’s Cancers Research Grant (WEWC140014).

The endometriosis GWAS was supported by a grant from the Wellcome Trust (WT084766/Z/08/Z) and makes use of WTCCC2 control data generated by the Wellcome Trust Case-Control Consortium. A full list of the investigators who contributed to the generation of these data is available from http://www.wtccc.org.uk. Funding for the WTCCC project was provided by the Wellcome Trust under awards 076113 and 085475. The QIMR study was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia (241944, 339462, 389927, 389875, 389891, 389892, 389938, 443036, 442915, 442981, 496610, 496739, 552485 and 552498), the Cooperative Research Centre for Discovery of Genes for Common Human Diseases (CRC), Cerylid Biosciences (Melbourne) and donations from N. Hawkins and S. Hawkins.

The COGS project is funded through a European Commission's Seventh Framework Programme grant (agreement number 223175 HEALTH F2 2009-223175); the Genetic Associations and Mechanisms in Oncology (GAME-ON): a NCI Cancer Post-GWAS Initiative (U19-CA148112); the Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). Funding of the constituent studies was provided by the California Cancer Research Program (00-01389V-20170, N01-CN25403, 2II0200); the Canadian Institutes of Health Research (MOP-86727); Cancer Australia;
Cancer Council Victoria; Cancer Council Queensland; Cancer Council New South Wales; Cancer Council South Australia; Cancer Council Tasmania; Cancer Foundation of Western Australia; the Cancer Institute of New Jersey; Cancer Research UK (C490/A6187, C490/A10119, C490/A10124); the Danish Cancer Society (94-222-52); the ELAN Program of the University of Erlangen-Nuremberg; the Eve Appeal; the Helsinki University Central Hospital Research Fund; Helse Vest; the Norwegian Cancer Society; the Norwegian Research Council; the Ovarian Cancer Research Fund; Nationaal Kankerplan of Belgium; the L & S Milken Foundation; the Polish Ministry of Science and Higher Education (4 PO5C 028 14, 2 PO5A 068 27); the Roswell Park Cancer Institute Alliance Foundation; the US National Cancer Institute (K07-CA095666, K07-CA80668, K07-CA143047, K22-CA138563, N01-CN55424, N01-PC67001, N01-PC067010, N01-PC035137, P01-CA017054, P01-CA087880, P30-CA150383, P30-CA008748, P50-CA159981, P50-CA105009, P50-CA136393, R01-CA149429, R01-CA014089, R01-CA016056, R01-CA17054, R01-CA049449, R01-CA050385, R01-CA50419, R01-CA58598, R01-CA58860, R01-CA61107, R01-CA61132, R01-CA63678, R01-CA63682, R01-CA67262, R01-CA071766, R01-CA074850, R01-CA080978, R01-CA083918, R01-CA087538, R01-CA092044, R01-CA095023, R01-CA122443, R01-CA112523, R01-CA114343, R01-CA126841, R01-CA136924, R03-CA113148, R03-CA115195, U01-CA069417, U01-CA071966 and Intramural research funds); the NIH/National Center for Research Resources/General Clinical Research Center (MO1-RR000056); the US Army Medical Research and Material Command (DAMD17-01-1-0729, DAMD17-02-1-0666, DAMD17-02-1-0669, W81XWH-07-0449, W81XWH-10-1-02802); the US Public Health Service (PSA-042205); The National Health and Medical Research Council of Australia (199600 and 400281); the German Federal Ministry of Education and Research of Germany Programme of Clinical Biomedical Research (01GB 9401); the State of Baden-Wurttemberg through Medical Faculty of the University of Ulm (P.685); the German Cancer Research Center; the Minnesota Ovarian Cancer Alliance; the Mayo Foundation; the Fred C. and Katherine B. Andersen Foundation; the Lon V. Smith Foundation (LVS-39420); the Oak Foundation; the OHSU Foundation; the Mermaid I project; the Rudolf-Bartling Foundation; the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge,
Imperial College London, University College Hospital “Womens Health Theme” and the Royal Marsden Hospital; WorkSafeBC 14.

Investigator-specific funding:

Y.L. was supported by the NHMRC Early Career Fellowship. D.R.N. was supported by the NHMRC Fellowship (339462 and 613674) and the Australian Research Council (ARC) Future Fellowship (FT0991022) schemes. A.P.M. was supported by a Wellcome Trust Senior Research Fellowship. G.W.M. was supported by the NHMRC Fellowships Scheme (339446, 619667). K.T.Z. was supported by a Wellcome Trust Research Career Development Fellowship (WT085235/Z/08/Z). G.C.T. is supported by the National Health and Medical Research Council. S.M. was supported by an ARC Future Fellowship.

Acknowledgement

We acknowledge with appreciation all the individuals who participated in the QIMR and Oxford endometriosis studies and in the OCAC studies, and the many hospital directors and staff, gynecologists, general practitioners and pathology services who provided assistance with confirmation of diagnoses, and the many research assistants and interviewers for assistance with the studies. For OCAC studies, we thank: D. Bowtell, A. deFazio, D. Gertig, A. Green, P. Parsons, N. Hayward, P. Webb and D. Whiteman (AUS); G. Peuteman, T. Van Brussel and D. Smeets (BEL); L. Gacucova (HMO); P. Schurmann, F. Kramer, W. Zheng, T. W. Park, Simon, K. Beer-Grondke and D. Schmidt (HJO); S. Windebank, C. Hilker and J. Vollenweider (MAY); the state cancer registries of AL, AZ, AR, CA, CO, CT, DE, FL, GA, HI, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WYL (NHS); L. Paddock, M. King, L. Rodriguez-Rodriguez, A. Samoila, and Y. Bensman (NJO); M. Sherman, A. Hutchinson, N. Szeszenia-Dabrowska, B. Peplonska, W. Zatonski, A. Soni, P. Chao and M. Stagner (POL); C. Luccarini, P. Harrington the SEARCH team and ECRIC (SEA); I. Jacobs, M. Widschwendter, E. Wozniak, N. Balogun, A. Ryan, C. Karpinskyj, and J. Ford (UKO); Carole Pye (UKR); A. Amin Al Olama, J. Dennis, E. Dicks, K. Michilaïdou, K. Kuchenbaker (COGS).
Conflict of Interest Statement

K.T.Z. has been a member of scientific advisory boards for AbbVie, Inc., Bayer Pharma AG and Roche Diagnostics.

Appendix

The International Endogene Consortium

Carl A. Anderson\textsuperscript{1,2}, Scott D. Gordon\textsuperscript{3}, Qun Guo\textsuperscript{4}, Anjali K. Henders\textsuperscript{3}, Ann Lambert\textsuperscript{5}, Sang Hong Lee\textsuperscript{6}, Peter Kraft\textsuperscript{7}, Stephen H. Kennedy\textsuperscript{5}, Stuart Macgregor\textsuperscript{3}, Nicholas G. Martin\textsuperscript{3}, Stacey A. Missmer\textsuperscript{4}, Grant W. Montgomery\textsuperscript{3}, Andrew P. Morris\textsuperscript{1}, Dale R. Nyholt\textsuperscript{3}, Jodie N. Painter\textsuperscript{3}, Fenella Roseman\textsuperscript{5}, Susan A. Treloar\textsuperscript{8}, Peter M. Visscher\textsuperscript{9}, Leanne Wallace\textsuperscript{1}, Krina T. Zondervan\textsuperscript{1,5}.

\textsuperscript{1}Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK, \textsuperscript{2}Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK, \textsuperscript{3}Queensland Institute of Medical Research, Herston, QLD, Australia, \textsuperscript{4}Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, \textsuperscript{5}Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, Oxford, UK, \textsuperscript{6}Queensland Brain Institute, The University of Queensland, Brisbane, QLD 4072, Australia, \textsuperscript{7}Harvard School of Public Health, Boston, MA, USA, \textsuperscript{8}Centre for Military and Veterans' Health, The University of Queensland, Mayne Medical School, QLD, Australia, \textsuperscript{9}The University of Queensland Diamantina Institute, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia.
References


**Figure Legends**

**Figure 1. Genetic risk prediction between endometriosis and EOC histotypes.** a) EOC histotypes as discovery and endometriosis as target; b) endometriosis as discovery and EOC histotypes as target; c) endometriosis as discovery and EOC histotypes as target, after the exclusion of women with endometriosis in the ovarian cancer case-control set. The figures show the association (y-axis: $-\log_{10}P$) between genetic risk scores calculated from the discovery set and the target disease. The colour coding denotes the P-value bins used to select SNPs from the discovery set. The dashed red line marks the significance threshold (P=0.05). The genetic risk scores were calculated from all platform-overlapping SNPs without LD clumping.
Table 1. Array heritability estimated from iCOGS array for invasive EOC, stratified by histotypes.

<table>
<thead>
<tr>
<th>EOC histotype</th>
<th>N case/control (relatedness &lt; 0.1)</th>
<th>K</th>
<th>$h^2_g$ % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>high-grade serous</td>
<td>4121/21663 (4098/21242)</td>
<td>0.0055</td>
<td><strong>8.8 (6.8-10.8)</strong></td>
</tr>
<tr>
<td>low-grade serous</td>
<td>363/21663 (362/21242)</td>
<td>0.0005</td>
<td>0.0 (0-9.3)</td>
</tr>
<tr>
<td>endometrioid</td>
<td>1350/21663 (1342/21242)</td>
<td>0.001</td>
<td><strong>3.2 (0.06-6.3)</strong></td>
</tr>
<tr>
<td>mucinous</td>
<td>662/21663 (658/21242)</td>
<td>0.0005</td>
<td>0.0 (0-5.4)</td>
</tr>
<tr>
<td>clear cell</td>
<td>621/21663 (620/21242)</td>
<td>0.0005</td>
<td><strong>6.7 (0.3-13.1)</strong></td>
</tr>
<tr>
<td>all invasive EOC</td>
<td>10014/21242 (10065/21663)</td>
<td>0.009</td>
<td><strong>5.6 (4.4-6.7)</strong></td>
</tr>
</tbody>
</table>

N case/control (relatedness < 0.1): case/control sample size, and case/control sample size restricting pairwise genetic relatedness between individuals less than 0.1 (see supplementary Table 3 for comparison of results using the cutoff of 0.05); K: disease prevalence of EOC histotype, defined as the lifetime risk of invasive ovarian cancer (~0.9%, see Methods) times the fraction of the corresponding EOC histotype; $h^2_g$ (95% CI): array heritability and its 95% confidence intervals that was estimated using ovarian cancer iCOGS data, while adjusting for ten principal components and study sites (the estimates with P<0.05 are in bold).
Figure 1a
Endometriosis as discovery

Ovarian cancer as target

Figure 1c